GlassScriptPhysician profile
Thomas K Kramer
NPI 1083635742
$2,118.58
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $478 · 2021: $242 · 2022: $365 · 2023: $231 · 2024: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $512.14 | 2019-2023 | |
| Boston Scientific Corporation | $275.35 | 2019-2022 | |
| Abbott Laboratories | $244.43 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $213.81 | 2019-2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $145.87 | 2019-2024 | |
| Amgen INC. | $138.35 | 2020-2023 | Repatha |
| Abiomed | $125.19 | 2022 | |
| Medtronic, INC. | $114.79 | 2023 | Corevalve Evolut R, Onyx Frontier |
| Medtronic Vascular, INC. | $105.77 | 2019 | |
| Philips North America LLC | $49.42 | 2020 | |
| Atricure, INC. | $41.71 | 2024 | |
| Pfizer INC. | $27.78 | 2019-2020 | |
| Chiesi USA, INC. | $22.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.35 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $16.62 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.60 | 2019 | |
| Teleflex LLC | $15.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.